Predictive Healthcare for Multiple Sclerosis

There are many different treatment options for Multiple Sclerosis and doctors need more data-driven insights to give themselves, and their patients, confidence in selecting the right treatment for them. Together with a doctors’ network called NeuroTransData, PwC has developed a Predictive Healthcare solution for Multiple Sclerosis – one that acts as a trusted, data-driven second opinion on Multiple Sclerosis treatments.

ITX Pharma & Life Sciences Virtual Round Table

Learn the latest news at our next international webinar
“ITX Pharma & Life Sciences Virtual Round Table” related to the ECJ Boehringer Ingelheim case.

  • Date:             Tuesday, 22 May 2018
  • Time:             1pm – 2pm CET
  • Login:            Please register here

I am looking forward to sharing this event with you.

Webinar on US Tax Reform for Pharma & Life Science

In December the United States enacted the most comprehensive tax reform in more than 30 years. For the Pharmaceutical and Life Sciences sector, the changes won’t just impact US based businesses but companies based outside the US who trade there.

Join PwC’s tax and industry specialists in a live webinar from New York.

Our specialists will be available to take questions following the presentation.

15 May 2018 | 14:00 BST (London) / 15:00 CEST (Paris) / 9:00AM EST (New York)

Presenter: Kathy Michael, PwC’s US Pharmaceutical & Life Sciences Tax Sector Leader

Access instructions:  Click here to register and access the webinar.
If you cannot view the webinar on your PC, you may dial in to the audio-only phone line:
+1 651 291 3245 / Passcode:  448492 #

If you have any questions please don’t hesitate to contact me.

New pharmaceutical ordinance in Switzerland

Have you already heard about the new medical drug ordinance in Switzerland – especially about Art. 21?

Please find some details by clicking on the title. The article linked describes import regulations for drugs into Switzerland.
The most relevant take-away is:

  • A permission for trading medicines abroad (i.e. outside Switzerland) is not sufficient for the conclusion of manufacturing agreements.
  • With only such a permission, a Swiss company is not entitled to import medicines into Switzerland. The Swiss legislation on therapeutic products does not foresee any sufficient Good manufacturing practice (“GMP”) requirements for the qualified person that are required to monitor and qualify the production of medicines.

Does the new medical drug ordinance have an impact on your supply chain (commercial, VAT, Customs, regulatory license, regulatory permission, ERP etc.)?

Let’s discuss further.

Invitation to the event: PwC Pharma & Life Sciences Get together

I am pleased to invite you to our Pharma & Life sciences
Get together.

During our Get together, we will talk about VAT, customs, direct tax and data privacy issues in the pharmaceutical and life science sector.

  • Date:             Thursday, 26 April 2018
  • Time:             8:30 – 10:30 am
  • Place:            PwC, St. Jakobs-Strasse 25, 4002 Basel

Take a look at our complete handout here.